Transcode Therapeutics, Inc. (RNAZ) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Transcode Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company operates in a single segment and is currently developing its lead candidate, TTX-MC138 (an oligonucleotide conjugated to an iron oxide nanoparticle), and Seviprotimut-L (a polyvalent antigen vaccine for melanoma, acquired via the Polynoma acquisition in October 2025). The company has not generated any revenue from product sales and has not achieved profitable operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17,785,071) | $(12,085,413) |
| Net Loss Attributable to Common Stockholders | $(19,510,296) | $(12,085,413) |
| Net Loss Per Share (Basic & Diluted) | $(21.28) | $(70.16) |
| Cash and Cash Equivalents (End of Period) | $12,835,454 | $11,569,154 |
| Net Cash Used in Operating Activities | $(4,978,067) | $(3,096,707) |
| Total Assets | $157,164,882 | $162,398,689 |
| Total Liabilities | $12,643,694 | $10,518,687 |
| Stockholders' Equity | $1,251,427 | $10,335,466 |
Note: The company holds significant intangible assets ($114.3M) and goodwill ($25.7M) related to the Polynoma acquisition. Series A Non-Voting Convertible Preferred Stock is classified as temporary equity with a carrying value of $143.3M.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly to $17.8M from $3.2M in Q1 2025. This was driven primarily by a one-time $10.4M non-cash charge for acquired in-process research and development (IPR&D) related to the Unleash Immuno Oncolytics licensing agreement signed in March 2026.
- Research & Development (R&D): R&D expenses rose to $5.1M from $2.2M, excluding the IPR&D charge, due to increased clinical trial spending and drug production costs.
- General & Administrative (G&A): G&A expenses increased to $2.2M from $0.95M, reflecting higher professional fees (legal, financial advisory) related to the Polynoma acquisition and the Unleash license.
- Other Income/Expense: The company recognized a $125k loss on the change in fair value of warrant liabilities, a significant improvement from the $9.2M loss in Q1 2025 (which included the exercise of Series D warrants).
- Equity Structure: The company issued Series C Non-Voting Convertible Preferred Stock in March 2026 as consideration for the Unleash license. Additionally, the company accrued $1.7M in paid-in-kind dividends on Series A Preferred Stock.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the issuance date without additional capital. Cash on hand ($12.8M) plus an expected $2.3M reimbursement from DEFJ is projected to fund operations only through approximately year-end 2026.
- Financing Activities: On April 6, 2026 (subsequent to period end), the company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing for the sale of up to $14M of common stock. Additionally, the company received a $1.0M convertible note (gross proceeds $0.95M) under this agreement on April 16, 2026.
- Clinical Pipeline: The Phase I/II trial for TTX-MC138 is ongoing. A Phase 2a trial is expected to commence in the first half of 2026. The company plans to integrate Seviprotimut-L development.
- Legal Proceedings: On April 24, 2026, Wheeler Bio, Inc. filed a lawsuit against Polynoma and Transcode alleging breach of contract and intentional interference with contractual relations regarding manufacturing services. The company disputes these claims.
- Nasdaq Compliance: The company's stockholders' equity does not currently meet Nasdaq listing requirements. Management expects to regain compliance upon obtaining stockholder approval for the conversion of preferred stock, though there is no guarantee.
- Internal Controls: Management identified a material weakness in internal control over financial reporting related to transactions arising from the Polynoma acquisition.
Key Facts for Investor Verification
- Cash Runway: Verify the timing of the expected $2.3M reimbursement from DEFJ and the sufficiency of the $12.8M cash balance to fund operations through year-end 2026.
- Financing Execution: Confirm the status of the Yorkville SEPA and the disbursement of the second tranche of the convertible note ($5.0M principal).
- Stockholder Approval: Monitor the outcome of the required stockholder votes for the conversion of Series A, B, and C Preferred Stock, which is critical for Nasdaq compliance and capital structure.
- Legal Exposure: Assess the potential financial impact of the Wheeler Bio litigation filed in April 2026.
- Unleash Integration: Evaluate the progress of the Unleash licensing program, which resulted in a $10.4M non-cash expense, and its impact on future R&D burn rates.